AstraZeneca’s Faslodex approved for new indication in the US
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
List view / Grid view
News
Lilly presents new data from the UNCOVER-2 trial of ixekizumab
8 March 2016 | By Victoria White
In UNCOVER-2, patients with plaque psoriasis who did not respond to etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab...
FDA accepts for review a new sBLA for Keytruda in NSCLC
8 March 2016 | By Victoria White
The FDA has accepted for review a new supplemental Biologics License (sBLA) for Merck’s Keytruda (pembrolizumab) to include data from KEYNOTE-010...
More access to morning after pill in Europe than ever before
8 March 2016 | By Victoria White
New research looks at women's awareness of over-the-counter access to emergency contraceptives in Europe...
AbbVie and Boehringer Ingelheim collaborate on BI 655066
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
SMC accepts three medicines for use in NHS Scotland; rejects two
7 March 2016 | By Victoria White
The Scottish Medicines Consortium (SMC) has accepted three new medicines for routine use in NHS Scotland.
New data for Enstilar foam spray presented at AAD
7 March 2016 | By Victoria White
These data show the enhanced local bioavailability of calcipotriol/betamethasone dipropionate in the foam spray vehicle results from supersaturation...
FSA grants Fast Track designation for MEDI8852
7 March 2016 | By Victoria White
MedImmune has received Fast Track designation from the FDA for MEDI8852 for the treatment of patients hospitalised with Type A strain influenza...
CPhI South East Asia opens as Indonesia encourages foreign investment
7 March 2016 | By CPhI
CPhI South East Asia, organised by UBM EMEA, will take place at the Jakarta International Expo, Indonesia, from 6th-8th April 2016...
Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
Study shows Victoza reduces the risk of major adverse cardiovascular events
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
First patient dosed in BAX 826 haemophilia A Phase I trial
4 March 2016 | By Victoria White
BAX 826 is a next-generation rFVIII treatment based on the full length Advate that uses proprietary polysialic acid technology to extend its circulating half-life...
DiscoverX and the SGC partner to make an annotated collection of >600 kinase inhibitors freely available
4 March 2016 | By DiscoverX
DiscoverX Corporation announced its partnership with the Structural Genomics Consortium (SGC)...
Peter J. Arduini elected to the board of Bristol-Myers Squibb
4 March 2016 | By Victoria White
Mr. Arduini is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company...
Phase I/II data for neoGAA in Pompe disease presented
4 March 2016 | By Victoria White
Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA...
